feed,title,long_url,short_url
Benzinga,Adamis Pharma Recalls Allergy Treatment Symjepi For Potential Manufacturing Defect,https://benzinga.com/general/biotech/22/03/26239405/adamis-pharma-recalls-allergy-treatment-symjepi-for-potential-manufacturing-defect,https://bit.ly/3wo0Jlv
Benzinga,Why ORIC Pharmaceuticals Shares Are Plunging Today,https://benzinga.com/general/biotech/22/03/26236374/why-oric-pharmaceuticals-shares-are-plunging-today,https://bit.ly/3ipl2XB
Benzinga,FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer,https://benzinga.com/general/biotech/22/03/26238387/fda-approves-second-indication-for-mercks-keytruda-in-endometrial-cancer,https://bit.ly/3JwEWvL
Benzinga,Terns Reports Topline Results from Early-Stage NASH Study,https://benzinga.com/general/biotech/22/03/26237656/terns-reports-topline-results-from-early-stage-nash-study,https://bit.ly/3IxvLto
